Cargando…

Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?

BACKGROUND: Leukocyte infiltration into the central nervous system is an important feature of multiple sclerosis (MS) pathology. Among the infiltrating cells, monocytes comprise the largest population and are considered to play a dual role in the course of the disease. The enzyme tissue transglutami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sestito, Claudia, Brevé, John J. P., van Eggermond, Marja C. J. A., Killestein, Joep, Teunissen, Charlotte E., van Rossum, Joram, Wilhelmus, Micha M. M., Drukarch, Benjamin, van den Elsen, Peter J., van Dam, Anne-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740592/ https://www.ncbi.nlm.nih.gov/pubmed/29268771 http://dx.doi.org/10.1186/s12974-017-1035-y

Ejemplares similares

Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients
por: Sestito, Claudia, et al.
Publicado: (2018)

Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
por: Sestito, Claudia, et al.
Publicado: (2021)

Is monocyte- and macrophage-derived tissue transglutaminase involved in inflammatory processes?
por: Chrobok, Navina L., et al.
Publicado: (2016)

Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions
por: Chrobok, Navina L, et al.
Publicado: (2019)

Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
por: Chrobok, Navina L., et al.
Publicado: (2018)

Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
por: Chrobok, Navina L., et al.
Publicado: (2018)

Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1(gfp/gfp) mice
por: Chrobok, Navina L., et al.
Publicado: (2016)

The Transglutaminase-2 Interactome in the APP23 Mouse Model of Alzheimer’s Disease
por: Wilhelmus, Micha M. M., et al.
Publicado: (2022)

Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer’s disease mouse models
por: Wilhelmus, Micha M. M., et al.
Publicado: (2016)

Absence of tissue transglutaminase reduces amyloid‐beta pathology in APP23 mice
por: Wilhelmus, Micha M. M., et al.
Publicado: (2022)

Tissue Transglutaminase Promotes Early Differentiation of Oligodendrocyte Progenitor Cells
por: Espitia Pinzon, Nathaly, et al.
Publicado: (2019)

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model
por: van der Wildt, Berend, et al.
Publicado: (2018)

Tissue transglutaminase in astrocytes is enhanced by inflammatory mediators and is involved in the formation of fibronectin fibril-like structures
por: Espitia Pinzón, Nathaly, et al.
Publicado: (2017)

gMS-Classifier1 does not predict disability progression in multiple sclerosis
por: van Rossum, Johannis A, et al.
Publicado: (2018)

Astrocyte-Derived Tissue Transglutaminase Interacts with Fibronectin: A Role in Astrocyte Adhesion and Migration?
por: van Strien, Miriam E., et al.
Publicado: (2011)

Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination
por: Espitia Pinzon, Nathaly, et al.
Publicado: (2017)

Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter
por: Espitia Pinzon, Nathaly, et al.
Publicado: (2014)

Thinking about the action potential: the nerve signal as a window to the physical principles guiding neuronal excitability
por: Drukarch, Benjamin, et al.
Publicado: (2023)

Transglutaminases in Monocytes and Macrophages
por: Sun, Huifang, et al.
Publicado: (2018)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography
por: van der Wildt, Berend, et al.
Publicado: (2016)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Brain region-specific gene expression profiles in freshly isolated rat microglia
por: Doorn, Karlijn J., et al.
Publicado: (2015)

Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients
por: Prins, Marloes, et al.
Publicado: (2014)

TCR V α- and V ß-Gene Segment Use in T-Cell Subcultures Derived from a Type-III Bare Lymphocyte Syndrome Patient Deficient in MHC Class-II Expression
por: Lambert, M., et al.
Publicado: (1992)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [(18)F]DPA714 PET
por: Hagens, Marloes H. J., et al.
Publicado: (2018)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

Induction of tissue transglutaminase in human peripheral blood monocytes
Publicado: (1984)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Hadron Production in Two-Photon Collisions at LEP
por: Van Rossum, Wilhelmus Lambertus
Publicado: (1998)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r0njfml7q6juls8crjcvurodjs